Since CHK2 shows a more significant increased in both cell lines tested, we examine whether blocking ixazomib-induced pCHK2 would lead to a more robust antitumor response in DLBCL cells. This evidence concerns the gene CHEK2 and diffuse large B-cell lymphoma.